In vitro and in vivo evaluation of the indoloquinone EO-9 (NSC 382 459) against human small cell carcinoma of the lung.
As the indoloquinone EO-9 has previously shown activity in several tumor model systems it was evaluated against four human small cell lung cancer cell lines by the clonogenic assay. In two cell lines (Nyh and Tol), exponential dose-response curves were achieved with both 1 h and continuous exposure, whereas no cell kill was obtained in the other two cell lines (69 and 592) when tested with 1 h incubation up to 0.25 microgram/ml. When the cells were exposed to drug in vitro, flow cytometric DNA analysis showed perturbations in the cell cycle distribution of the most sensitive cell line (Tol) at a lower EO-9 concentration than in the less sensitive cel line (592). This in vitro predicted difference in EO-9 sensitivity between two of the cell lines (592 and Tol) was confirmed when the cell lines were heterotransplanted to nude mice.
Roed
H
H
Department of Oncology B, Finsen Institute, Copenhagen, Denmark.
Aabo
K
K
Vindeløv
L
L
Spang-Thomsen
M
M
Christensen
I B
IB
Hansen
H H
HH
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001388:Aziridines; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002460:Cell Line; D003114:Colony-Forming Units Assay; D004305:Dose-Response Relationship, Drug; D006801:Humans; D045563:Indolequinones; D007211:Indoles / Q000008:administration & dosage / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy*; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D011809:Quinones / Q000008:administration & dosage / Q000627:therapeutic use*; D014410:Tumor Stem Cell Assay
D000970:Antineoplastic Agents; D001388:Aziridines; D045563:Indolequinones; D007211:Indoles; D011809:Quinones; C060817:apaziquone